Sanofi
Human Cytomegalovirus Immunogenic Composition
Last updated:
Abstract:
The invention relates to an immunogenic composition comprising an HCMV gH/gL/UL128/UL130/UL131 pentameric complex antigen and a TH1-inducing adjuvant. It further relates to the immunogenic composition for use as an HCMV vaccine.
Status:
Application
Type:
Utility
Filling date:
15 Oct 2020
Issue date:
28 Jan 2021